TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00921388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Varenicline and smoking cessation counseling
Description: All subjects receive smoking cessation counseling and varenicline 0.5mg daily for three days then twice a day for the next four days; then 1 mg twice a day for 11 weeks. Counseling is integrated within the exercise or relaxation treatment program.

Intervention type: OTHER
Group type: OTHER
Intervention: Varenicline and smoking cessation counseling
Description: All subjects receive smoking cessation counseling and varenicline 0.5mg daily for three days then twice a day for the next four days; then 1 mg twice a day for 11 weeks. Counseling is integrated within the exercise or relaxation treatment program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise or relaxation treatment
Description: One hour exercise sessions twice a week for 8 weeks, then once a week for 8 weeks, then once every other week for 4 weeks. Subjects in the control group receive a relaxation program that controls for contact time.
Study: NCT03680534

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal preparation
Description: Root canals from lower premolars with extraction indicated were prepared previous to being extracted with either the Reciproc Blue, the WaveOne Gold or the XP EndoShaper single-file techniques.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal preparation
Description: Root canals from lower premolars with extraction indicated were prepared previous to being extracted with either the Reciproc Blue, the WaveOne Gold or the XP EndoShaper single-file techniques.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal preparation
Description: Root canals from lower premolars with extraction indicated were prepared previous to being extracted with either the Reciproc Blue, the WaveOne Gold or the XP EndoShaper single-file techniques.
Study: NCT04170088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid intradermal injections were used for treatment of melasma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% Normal Saline
Description: Normal saline used for comparision of efficacy of tranexamic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% Normal Saline
Description: Normal saline used for comparision of efficacy of tranexamic acid
Study: NCT03475342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Ampoules and packaging for both arms will be identical in appearance.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ampoules and packaging for both arms will be identical in appearance.
Study: NCT01979718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirrored Virtual reality
Description: Patients are required to look at the images of both lower extremities ranged from the perineal area to the foot. Virtual reality system records in real-time method both lower extremities. Following the validity assessement mirrored image of the surgeried lower extremity is re-formed using the virtusal reality system flipping the image of lower extremity not-surgeried and being calibration for the symmetricity.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirrored Virtual reality
Description: Patients are required to look at the images of both lower extremities ranged from the perineal area to the foot. Virtual reality system records in real-time method both lower extremities. Following the validity assessement mirrored image of the surgeried lower extremity is re-formed using the virtusal reality system flipping the image of lower extremity not-surgeried and being calibration for the symmetricity.
Study: NCT01219101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene citrate with ethinyl esteradiol
Description: Clomiphene citrate is used in combination of ethinyl estradiol (0.05 mg for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate with plasebo
Description: Clomiphene citrate is used in combination of placebo (for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
Study: NCT00498043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP14 induction regimen
Description: R-CHOP14 induction regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-ACVBP14 induction regimen
Description: R-ACVBP14 induction regimen
Study: NCT03082677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib beginning between day +100 to +150 at a dose of 4 mg orally once per week (3 weeks on/ 1 week off).
Study: NCT04410965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERIFLUNOMIDE
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT04118543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Each participant assigned to this intervention arm will start with a progressive cardiovascular warm-up for 10mins. The main exercise session will consist of resistance and cardiovascular based exercises targeting the whole body, which will last for 35-40mins. A cool-down period will follow lasting 5-10mins.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-Exercise Group
Description: Each participant assigned to this intervention arm will start with a warm-up for 10mins, which will be controlled in order to reduce any cardiovascular training effects. The sham-exercise sessions will consist of stretching, coordination and balance activities and very low-level cardiovascular activities that mimic the types of exercise done in the intervention group. This will last for 35-40mins, followed by a 5-10min cool-down.
Study: NCT00953953

Intervention type: DEVICE
Intervention: Phillips ultrasound system
Description: The tissue doppler imaging color images will be acquired from two, three, and four-chamber apical views to assess the longitudinal contraction of the left ventricle.

Intervention type: DEVICE
Intervention: Phillips ultrasound system
Description: The tissue doppler imaging color images will be acquired from two, three, and four-chamber apical views to assess the longitudinal contraction of the left ventricle.

Intervention type: DEVICE
Intervention: Phillips ultrasound system
Description: The tissue doppler imaging color images will be acquired from two, three, and four-chamber apical views to assess the longitudinal contraction of the left ventricle.

Intervention type: DEVICE
Intervention: Phillips ultrasound system
Description: The tissue doppler imaging color images will be acquired from two, three, and four-chamber apical views to assess the longitudinal contraction of the left ventricle.
Study: NCT03780751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Description: COPE-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and cognitive-behavioral interventions (e.g., thought diaries, challenging of maladaptive thought patterns, behavioral analysis). Participants are encouraged to practice exercises between sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based treatment
Description: MIND-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and mindfulness-based exercises (e.g., breathing meditation, body scan, sitting meditation).
Study: NCT01590745

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMS Therasonic 460 Primo Ultrasound therapy
Description: 1MHz / 1.0W/cm square probe for 15 minutes per session for 20 sessions.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: EMS Therasonic 460 Primo Ultrasound therapy
Description: 1MHz / 1.0W/cm square probe for 15 minutes per session for 20 sessions.
Study: NCT00833027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: Sitagliptin 100 mg/day - tablet for 24 weeks
Study: NCT02116842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% bupivacaine
Description: Epidural block in early labour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.075% bupivacaine
Description: Epidural block in early labour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 µg fentanyl
Description: Given with different doses of bupivacaine in epidural block.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 µg fentanyl
Description: Given with different doses of bupivacaine in epidural block.
Study: NCT00876252

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC43

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC43

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC43

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl
Study: NCT02288000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Memantine will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the placebo will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
Study: NCT01445613

Intervention type: DEVICE
Group type: OTHER
Intervention: RX Acculink Carotid Stent System (RX Acculink)
Description: Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
Study: NCT02911142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide taken orally, daily at assigned dose level on days 1 to 10, up to 25mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: During cycle 1, rituximab will be administered on day 4 prior to the start of EPOCH. During cycles 2 to 6, rituximab will be administered on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: During cycle 1, Prednisone 60 mg/m2 /day PO days 6 to 10. During cycles 2-6, Prednisone 60 mg/m2 /day PO days 1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etopside
Description: During cycle 1, Etoposide 50 mg/m2 /day continuous intravenous infusion days 6 to 9. During cycles 2-6, Etoposide 50 mg/m2/day continuous intravenous infusion days 1 to 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: During cycle 1, Doxorubicin 10 mg /m2/day continuous intravenous infusion days 6 to 9. During cycles 2-6, Doxorubicin continuous intravenous infusion days 1 to 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: During cycle 1, Vincristine 0.4 mg/m2 /day continuous intravenous infusion days 6 to 9. During cycles 2-6, Vincristine continuous intravenous infusion days 1 to 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: During cycle 1, Cyclophosphamide 750 mg/m2 day 10. During cycles 2-6, Cyclophosphamide 750 mg/m2 day 5.
Study: NCT00640991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glulisine insulin, glargine insulin
Description: IV infusion of glulisine, SC injection of glargine
Study: NCT01929343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine following cue-induced craving
Description: as described in Arm Description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine following neutral stimulus
Description: as described in Arm Description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: as described in Arm Description
Study: NCT06055010

Intervention type: OTHER
Intervention: No interventions
Description: Considering the retrospective nature of this project and use of existing clinical and technical data, this project contains no interventions or prospective inclusion of healthy subjects / patients for the execution of experiments.

Intervention type: OTHER
Intervention: No interventions
Description: Considering the retrospective nature of this project and use of existing clinical and technical data, this project contains no interventions or prospective inclusion of healthy subjects / patients for the execution of experiments.
Study: NCT04576910

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccinated with Sabin IPV
Description: the 4th dose of polio vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccinated with Sabin IPV
Description: the 4th dose of polio vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccinated with Sabin IPV
Description: the 4th dose of polio vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccinated with bOPV
Description: the 4th dose of polio vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccinated with bOPV
Description: the 4th dose of polio vaccination
Study: NCT01970228

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 68Ga-citrate and 18F-FDG PET/CT imaging
Description: Single-day study of the two PET tracers

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 68Ga-citrate and 18F-FDG PET/CT imaging
Description: Single-day study of the two PET tracers

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 68Ga-citrate and 18F-FDG PET/CT imaging
Description: Single-day study of the two PET tracers
Study: NCT04406207

Intervention type: OTHER
Intervention: Demonstration of T cell responses
Description: Evaluation of HERVs-specific CD8+ T cells before and after hematopoietic stem cell transplantation. Comparison will be made in patients relapsing vs non relapsing patients.~The measurement of these responses will be done by dextramer, allowing precise and specific measurement of the lymphocytes directed against the HERVs of interest.
Study: NCT04306562

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: enteral nutrition supplement
Description: enteral nutrition supplement to reach a target of total dietary protein intake of 1.5 g/kg/day for at least 14 days from a preanesthetic clinic visit to a day of surgery.
Study: NCT02351011

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 x 10^6 MSCs
Description: Autologous, bone-marrow derived MSCs

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 x 10^6 MSCs
Description: Autologous, bone-marrow derived MSCs

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 x 10^6 MSCs
Description: Autologous, bone-marrow derived MSCs
Study: NCT01062698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase (rt-PA)/Actilyse
Description: Injection of 0.9 mg/kg for 60min with an initial 10% bolus injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase (rt-PA)/Actilyse
Description: Injection of 0.9 mg/kg for 60min with an initial 10% bolus injection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanic thrombectomy (MERCI, PENUMBRA, CATCH, SOLITAIRE)
Description: Mechanic thrombectomy
Study: NCT04433156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles
Study: NCT02567799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO 300 Oral Suspension
Description: Cohort 1: BIO 300 500 mg Cohort 2: BIO 300 1,000 mg Cohort 3: BIO 300 1,500 mg Cohort 4: BIO 300 Optimal dose (TBD) BIO 300 dose will be given daily, 7 days/week (Week 1, day 1 through week 6) The 2nd and 3rd dosing cohort (1,000 and 1,500 mg/day) will begin following the accrual of a minimum of 6 subjects at the previous dose level, dose escalation to the next BIO 300 dose level will be allowed to occur when a cohort has completed concurrent chemoradiotherapy with fewer than 33% Dose Limiting Toxicities (DLTs) attributed to BIO 300 Oral Suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: During the Concurrent Therapy period, paclitaxel 45 mg/m2 will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, paclitaxel 200 mg/m2 will be administered by intravenous drip two times, 21 days apart.
Study: NCT01072331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-513
Description: MP-513 10 mg, once a day, for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-513
Description: MP-513 20 mg, once a day, for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of MP-513
Description: MP-513 placebo, once a day, for 4 weeks
Study: NCT04257981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain stimulator v3.0
Description: Brain stimulator v3.0 will be used to deliver 1.5 mA current over the scalp corresponding to the primary motor cortex. The current will be delivered via two surface electrodes 5 × 5 cm placed on the scalp, validated by the previous research

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Control group
Description: The sham set-up will follow a similar protocol as the experimental group but the intensity of the current will be ceased after 30 seconds of stimulation. Participants in the Sham group will feel the identical sensation as the experimental group and will be unable to differentiate between actual and sham tDCS such procedure is validated in earlier studies
Study: NCT04608305

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100 medium dose (prime)
Description: Single administration of IIBR-100 1\*10E6 pfu/ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100 high-dose (prime)
Description: Single administration of IIBR-100 1\*10E7 pfu/ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100 high-dose (prime)
Description: Single administration of IIBR-100 1\*10E7 pfu/ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100 high-dose (prime)
Description: Single administration of IIBR-100 1\*10E7 pfu/ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100 low-dose (prime-boost)
Description: Two administrations of IIBR-100 1\*10E5 pfu/ml, 28 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100 low-dose (prime-boost)
Description: Two administrations of IIBR-100 1\*10E5 pfu/ml, 28 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100 low-dose (prime-boost)
Description: Two administrations of IIBR-100 1\*10E5 pfu/ml, 28 days apart

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo (single)
Description: Single administration of saline placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo (single)
Description: Single administration of saline placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo (single)
Description: Single administration of saline placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo (single)
Description: Single administration of saline placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo (single)
Description: Single administration of saline placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo (single)
Description: Single administration of saline placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo (single)
Description: Single administration of saline placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo (single)
Description: Single administration of saline placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo (single)
Description: Single administration of saline placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo (double)
Description: Two administrations of saline placebo, 28 days apart

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo (double)
Description: Two administrations of saline placebo, 28 days apart
Study: NCT02567799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: During the Concurrent Therapy period, area under the curve (AUC) = 2mg\* min/mL will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, carboplatin AUC = 6mg\*min/mL will be administered by intravenous drip two times, 21 days apart.
Study: NCT02018783

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cocorico
Description: Digital application for 60 seconds
Study: NCT02567799

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation treatment will be scheduled at the discretion of the investigator provided the subject has completed a minimum of 2 days of BIO 300 dosing. Subjects will receive radiation therapy 5 days per week, once daily fractions, 1.8-2.0 Gy per fraction, for 6-7 weeks.
Study: NCT00364650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Supplement
Description: 2 capsules twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04545879

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Raw garlic juice containing allicin
Description: Fresh garlic juice containing around 48mg allicin for 7 days
Study: NCT04170998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin 5mg
Description: Participants receive Evogliptin 5mg orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Evogliptin Placebo
Description: Participants receive placebo to match Evogliptin 5mg orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Participants receive Dapagliflozin orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: Participants receive Dapagliflozin orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ≥ 1000mg
Description: Metformin are administered at the same dose and formulation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin ≥ 1000mg
Description: Metformin are administered at the same dose and formulation.
Study: NCT01148901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab 5 mg/kg administered as an intravenous perfusion over a period of 2 hours at Weeks 0, 2, 6, and 14, as indicated in the Summary of Product Characteristics
Study: NCT02270281

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine 0.7 Mcg/kg/h
Description: CIF 0.7mcg/kg/h